Outcomes-based agreements (OBA) have been endorsed by US payers as the new frontier in the “paying-for-value” transformation. But if we move beyond the initial excitement and PR, where does pharma stand on risk-sharing and innovative contracting?
Click here to read the 65-page report from the Analytica Laser Contracting team for expert guidance:
It is time to take a seat at the negotiating table – the report includes in-depth perspectives from leaders at Harvard Pilgrim, Tesaro and many other OBA pioneers so you can set up for success.
Download your complimentary copy today and let me know your thoughts.